Trinity Capital Inc. Provides $20 Million in Growth Capital to Emboline, Inc. to Advance Interventional Heart Procedure Technology
MWN-AI** Summary
Trinity Capital Inc. has announced a significant commitment of $20 million in growth capital to Emboline, Inc., a MedTech firm dedicated to advancing interventional heart procedure technology aimed at reducing strokes and other complications. Emboline's flagship product, the Emboliner® Embolic Protection Catheter, is engineered to enhance the safety of minimally invasive heart procedures. This innovative device captures and removes potentially harmful debris that could travel to the brain and other vital organs, thereby safeguarding patient health during operations.
The funding from Trinity Capital is pivotal for Emboline as it approaches critical milestones, including the completion of the PROTECT H2H investigational device exemption clinical trial, which will generate essential clinical data for regulatory approval and eventual market launch. Scott Russell, President and CEO of Emboline, emphasized that the financing will bolster their manufacturing capabilities, expand their workforce, and facilitate the clinical and regulatory processes necessary for bringing the Emboliner system to patients globally.
Rob Lake, Senior Managing Director at Trinity Capital, expressed pride in partnering with Emboline and recognized the team's commitment to improving patient safety. The partnership underscores Trinity's mission of providing tailored debt solutions to innovative companies in the healthcare sector.
Based in Phoenix, Arizona, Trinity Capital is an international alternative asset manager focusing on delivering consistent investment returns by accessing private credit markets. Since its inception in 2008, the firm has deployed over $5.5 billion across 463 investments, demonstrating its robust position in the private credit landscape.
Emboline, located in Santa Cruz, California, remains a privately held company focused on technologies that mitigate embolic risks during cardiovascular procedures, with the Emboliner device currently under investigational status and not yet available for commercial sale.
MWN-AI** Analysis
Trinity Capital Inc. (Nasdaq: TRIN) has recently committed $20 million in growth capital to Emboline, Inc., an emerging player in the MedTech sector focused on enhancing the safety of interventional heart procedures. This partnership signals Trinity's strategic focus on companies that address critical healthcare challenges, particularly in the rapidly evolving cardiovascular market.
Evaluating this investment, several key points suggest a favorable outlook for Trinity Capital. First, the innovative Emboliner® Embolic Protection Catheter represents a significant advancement in minimizing complications during heart procedures—an area of high demand given the increasing prevalence of cardiovascular diseases. The successful transition of Emboline from clinical trials to market will be pivotal and could set a precedent for additional investments in similar healthcare technologies.
Furthermore, Trinity Capital’s reputation as a provider of tailored debt solutions in various high-growth sectors positions it well to capitalize on this investment. The company has a history of strategic deployments, having invested over $5.5 billion across multiple verticals since its inception. Given the growth trajectory of the MedTech market, driven by an aging population and rising healthcare spending, Trinity’s investment strategy appears aligned with long-term industry trends.
From a financial advising perspective, potential investors should consider the implications of this investment on Trinity Capital’s portfolio. The focus on life sciences and MedTech not only diversifies Trinity's exposure but enhances its growth potential. As Emboline embarks on the commercialization of the Emboliner system, successful outcomes could generate significant returns for Trinity, increasing shareholder value.
In conclusion, Trinity Capital's $20 million investment in Emboline Inc. could be seen as a strategic move within a promising sector. Investors looking for exposure to innovative healthcare technologies may find Trinity Capital’s strategic investments in companies like Emboline attractive, potentially yielding fruitful returns as the demand for safer medical procedures continues to rise.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
PHOENIX, March 11, 2026 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) ("Trinity"), a leading international alternative asset manager, today announced the commitment of $20 million in growth capital to Emboline, Inc. ("Emboline"), a MedTech company focused on reducing strokes and other complications during interventional heart procedures.
Emboline's proprietary Emboliner® Embolic Protection Catheter is designed to help make minimally invasive heart procedures safer by capturing and removing debris that could otherwise reach the brain and other vital organs. The Emboliner is composed of a flexible, conforming mesh that allows normal blood flow while providing protection during procedures. The company recently completed patient enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial, advancing its efforts to generate the clinical data needed for regulatory approval and the commercial launch of the Emboliner system.
"We're proud to partner with the Emboline team as they advance their mission to reduce strokes and other complications associated with heart procedures," said Rob Lake, Senior Managing Director at Trinity Capital. "The team's passion and dedication to improving patient safety is inspiring, and we're excited to support them as they expand access to the Emboline system."
"We are entering an important phase as we prepare for the commercial introduction of the Emboliner system," said Scott Russell, President and CEO of Emboline. "Trinity Capital's growth financing strengthens our ability to scale manufacturing, expand our team, and support the clinical and regulatory milestones that will bring this technology to patients worldwide."
This financing will support Emboline in preparing for the commercial launch of the Emboliner system while continuing to advance its platform of technologies aimed at reducing risk during minimally invasive heart procedures.
About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $5.5 billion across over 463 investments since inception in 2008 (as of December 31, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and Europe. For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn and X (@trincapital).
About Emboline
Emboline, Inc. is a privately held medical technology company based in Santa Cruz, California, focused on developing technologies designed to reduce embolic complications during transcatheter cardiovascular procedures. The company's lead product, the Emboliner® Embolic Protection Catheter, is designed to provide full cerebral and systemic embolic protection by capturing and removing debris that may be released during structural heart interventions and that could otherwise travel to the brain and other vital organs.
For more information, visit emboline.com.
The Emboliner® device is currently investigational and is not available for commercial sale.
SOURCE Trinity Capital Inc.
FAQ**
How will the $20 million growth capital from Trinity Capital Inc. TRIN enable Emboline to expedite its regulatory approval process for the Emboliner® device, and what impact could this have on the company's market entry timeline?
In what ways does Trinity Capital Inc. TRIN plan to support Emboline, Inc. beyond financial investment, particularly in areas such as team expansion and manufacturing scalability for the Emboliner system?
Given Trinity Capital Inc. TRIN's history of deploying over $5.5 billion in various sectors, how does this investment in Emboline fit within their overall investment strategy focusing on MedTech and life sciences?
What clinical and regulatory milestones does Emboline, Inc. aim to achieve with the help of the $20 million from Trinity Capital Inc. TRIN, and what are the potential implications for patient safety in interventional heart procedures?
**MWN-AI FAQ is based on asking OpenAI questions about Trinity Capital Inc. (NASDAQ: TRIN).
NASDAQ: TRIN
TRIN Trading
-1.28% G/L:
$14.535 Last:
468,659 Volume:
$14.58 Open:
